Discussing results, side effects and potential sources of pyrilutamide for hair loss treatment alongside RU58841 and other treatments such as Minoxidil and finasteride.
Women experienced severe reactions, including Topical Steroid Withdrawal (TSW), from using Winlevi (Clascoterone 1%) on their faces. Concerns were raised about the potential risks of higher concentrations, especially for hair loss treatment.
Stopping finasteride may reduce water retention or alter fat distribution, leading to a leaner face. Hormonal changes, like reduced DHT or increased estrogen, could cause these effects.
Zinc picolinate and saw palmetto may lower DHT but are less effective than finasteride. Finasteride and minoxidil are preferred treatments, with ketoconazole shampoo as a suggested addition.
The user plans to test for DHT, total testosterone, free testosterone, E2, SHBG, and prolactin while supplementing with vitamin D and monitoring ferritin levels. They are experiencing hairline thinning and are seeking advice on whether their approach is excessive or lacking.
AHK-Cu peptide is considered better than GHK-Cu for hair growth. The user is seeking recommendations for trusted AHK-Cu peptide brands with third-party testing.
The conversation discusses a new product from Actifolic, which combines RU58841 and GHK-CU for hair loss treatment. The participants are considering whether it's worth trying.
The user experienced significant hair regrowth using finasteride and dutasteride, with noticeable results after switching to dutasteride. Minoxidil was deemed unnecessary due to the restoration of the hairline and lack of hair follicles in bald spots.
Clascoterone, a topical anti-androgen, is generating interest for potentially fewer systemic side effects. Users are curious about its effectiveness and details like concentration and duration of use.
The conversation discusses hair loss treatments, specifically the use of RU58841 by individuals who did not respond to dutasteride. Users share experiences with maintaining hair using RU58841 and mention trying pyrilutamide and the upcoming availability of pp405.
PP405 is considered a potential new treatment for hair loss, compared to finasteride and minoxidil. There is skepticism about its effectiveness in humans, with anticipation for more information from an upcoming conference.
RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.
PP405 is a promising new treatment for hair loss that activates dormant stem cells in hair follicles, potentially bypassing the effects of DHT. It is currently in phase 2 trials and could be available between 2027 and 2030, but it is not considered a definitive cure.
Exploring potential treatments for hair loss, with the focus being on comparing RU58841 and Pyrilutamide. Finasteride, Dutasteride, oral Minoxidil, microneedling, topical Minoxidil, Biotin, Zinc, Vitamin D and Nizoral are also discussed as part of a treatment stack.
The conversation is about finding high-purity RU58841 solutions for hair loss treatment, with mentions of Anagenic, Selleckchem, MV Supplement, and rudirect.co.uk as potential sources. Users discuss their experiences and preferences regarding product quality and shipping.
Long-term RU58841 users discuss its effectiveness, with some finding it not worth the cost compared to other treatments like Dutasteride and Minoxidil. One user experienced side effects from a chemical company product, while another is regrowing hair after stopping RU58841.
A group buy for products to treat hair loss, such as Minoxidil, Finasteride and RU58841. Participants are interested in adding more people before ordering the next order.
The conversation is about the effectiveness of low-level laser therapy (LLLT) caps for hair regrowth. One user suggests saving money, implying LLLT caps may not be beneficial.
Increasing the dutasteride dose to 2.5 mg may significantly reduce DHT and promote hair regrowth, with similar side effects to lower doses. Some users combine dutasteride with minoxidil and finasteride for better results, but there are concerns about long-term effectiveness and availability.
User taking 1mg finasteride daily for 2 years, wants to block more scalp DHT. Seeks reference for additional topical DHT blockers like alfatradiol and fluridil.
GT20029 is a topical treatment that degrades androgen receptors to prevent hair thinning and loss, potentially offering fewer side effects than systemic treatments like finasteride. Concerns include its impact on hair texture and potential systemic effects, with market availability speculated in 3 to 5 years.
A user is seeking help to purchase and ship Alpecin DMG to the United States due to issues with eBay sellers. They prefer Alpecin DMG over minoxidil because of concerns about minoxidil's effects on insulin production, as they have diabetes.
Natural alternatives like omega-3, green tea, and pumpkin seeds are suggested for reducing DHT levels, but their effectiveness is questioned. Topical minoxidil and ketoconazole shampoo are recommended, with some users also considering low-dose finasteride and saw palmetto.
The user experienced no significant improvement in hair loss despite using Dutasteride, oral Minoxidil, and previously RU58841, and is uncertain if changes in medication or stopping RU58841 worsened the condition. Some users noted no change or slight improvement, while others suggested the possibility of Dutasteride causing issues.
Phase II for TDM-105795 for Androgenic Alopecia is set to begin in April 2023. The study aims to evaluate the efficacy and safety of TDM-105795 in male subjects.
Scientists discovered a sugar gel, 2dDR-SA, that increased hair growth in mice. Users discussed its potential, comparing it to other treatments like Minoxidil and finasteride.
The conversation is about the effectiveness and production of GT20029, a drug being developed as a topical androgen receptor degrader for hair loss, and whether it can fully degrade androgen receptors or only partially. It also discusses the drug's potential unique working mechanism and synthesis by a company called Anagen.